An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis
Research article published in Expert opinion on pharmacotherapy (2021)
Abstract
Introduction: Cancer-associated thrombosis (CAT) refers to the most common thromboembolic complication of cancer which is venous thromboembolism (VTE). CAT primary prophylaxis, treatment, and secondary prevention are challenging for the complexity of cancer patients, who exhibit hypercoagulability with concomitant-heightened bleeding risk.Areas covered: In this review, the author examines the role of low molecular weight heparins (LMWH), which have been the standard of care for CAT treatment for many years. Direct oral anticoagulants (DOACS) have practical advantages over subcutaneous LMWH, especially for long-term therapy. The author then discusses the results of two RCTs which separately compared the direct oral factor Xa inhibitors, apixaban or rivaroxaban, with placebo for CAT prophylaxis in ambulatory high-risk cancer patients and found that DOACS reduced VTE but increased bleeding. Finally, the author discusses four RCTS separately comparing an oral direct factor Xa inhibitor (edoxaban, rivaroxaban, or apixaban) with LMWH for CAT treatment. DOACS showed non-inferior efficacy, although rivaroxaban and edoxaban showed higher bleeding rates, especially in gastrointestinal cancers.Expert opinion: DOACS have a convenient route of administration and do not require laboratory monitoring, although choice of anticoagulants for CAT depends on factors such as tumor type, bleeding risk, concomitant drugs, and comorbidities.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.
Por qué esto importa para la hirudoterapia
Esta revisión narrativa resume la eficacia y seguridad de las heparinas de bajo peso molecular frente a los anticoagulantes orales directos (los inhibidores del Factor Xa apixaban, rivaroxaban y edoxaban) para la trombosis asociada al cáncer, señalando que en los RCTs que revisa, los agentes orales directos mostraron eficacia no inferior, pero el rivaroxaban y el edoxaban presentaron tasas de sangrado más altas, especialmente en los cánceres gastrointestinales, por lo que la elección del anticoagulante debe ser individualizada. Su relevancia para la ASH es como un mapa claro del panorama de la anticoagulación, el campo de la modulación de la coagulación en el que los péptidos inhibidores de la trombina del secreto de la sanguijuela medicinal son el antecedente histórico de los anticoagulantes dirigidos de hoy. La advertencia es que esta es una revisión que sintetiza los ensayos de otros autores en lugar de datos originales, refleja la interpretación del autor citado y la evidencia disponible hasta 2021, y se refiere a fármacos convencionales sin ningún agente derivado de sanguijuelas ni la hirudoterapia en el alcance.
Citación
An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis.
Cosmi · Expert opinion on pharmacotherapy, 2021
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 29, 2026 · Última actualización del sitio: June 18, 2026